Trial Profile
Safety of fondaparinux as routine VTE [venous thromboembolism] prophylaxis in medical ICU [intensive care unit] patients: an investigator initiated protocol.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions
- 27 Sep 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2007 New trial record.